Immutep’s cash position remains very strong with a cash and cash equivalent balance as at 31 December 2023 of approximately $103.7 million. With an expected cash reach till early CY2026, the Company is well financed to reach key milestones that will potentially add value to efti and IMP761.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMP:
- Immutep announces first patient enrolled, dosed in INSIGHT-005 trial
- Immutep receives constructive feedback on TACTI-004 trial
- Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
- Immutep receives EUR 1.595M R&D tax incentive from French government
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government
